Pascale Witz, MBA, is a Molecular Biologist and an Engineer; a global Pharmaceutical, MedTech and Diagnostics Executive, with 30 years’ experience leading businesses in the US and globally; a board member of public and private Life Science companies; an advisor to CEOs and Investment firms; a former Executive VP at Sanofi; a former CEO of a $2Bn Pharma business and a GE Healthcare veteran.
Pascale currently serves on the board of Fresenius Medical Care (FME), Horizon Therapeutics (HZNP) , Regulus Therapeutics (RGLS) and Perkin Elmer (PKI). She previously sat on the board of Savencia (SAVE), and Tesaro Bio (TSRO), until its acquisition by GSK.
Previously, Pascale was Executive VP and member of the Executive Committee of Sanofi, head of the Pharma and Consumer Healthcare Divisions (€15bn revenues), and head of the Global Diabetes and Cardiovascular Businesses (€7bn revenue).
Before that, Pascale was President and CEO of a fully integrated $2Bn pharmaceutical business (previously Amersham Health) at GE Healthcare.
Pascale has a proven track record in strategically repositioning businesses, driving operations that deliver results; Pascale has a reputation across the healthcare sector for vision, strength and effectiveness by achieving growth through implementing new strategies and driving operational success.
Pascale led teams who delivered significant outcomes for the business; launched multiple products across multiple disease area, and across three continents; lead large multifunctional teamwork across Development, Commercial and Market Access; strengthened the pipeline and repositioned the company as an innovation-leader thru licensing and partnerships; led several acquisitions and successful integrations; and led a digital transformation. Pascale established the first of its kind Joint Venture of a pharma company (Sanofi) with Verily (fka Google Life Sciences) for Diabetes (Onduo).